The current status of pharmacotherapy for the treatment of Parkinson's disease : transition from single-target to multitarget therapy
Copyright © 2019 Elsevier Ltd. All rights reserved..
Parkinson's disease (PD) is a neurodegenerative disorder characterized by degeneration of dopaminergic neurons. Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. Current treatment options provide symptomatic relief to the condition but are unable to reverse disease progression. The conventional single-target therapeutic approach might not always induce the desired effect owing to the multifactorial nature of PD. Hence, multitarget strategies have been proposed to simultaneously target multiple proteins involved in the development of PD. Herein, we provide an overview of the pathogenesis of PD and the current pharmacotherapies. Furthermore, rationales and examples of multitarget approaches that have been tested in preclinical trials for the treatment of PD are also discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Drug discovery today - 24(2019), 9 vom: 01. Sept., Seite 1769-1783 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheong, Siew L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 11.06.2020 Date Revised 11.06.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drudis.2019.05.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29721277X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29721277X | ||
| 003 | DE-627 | ||
| 005 | 20231225091512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2019.05.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0990.xml |
| 035 | |a (DE-627)NLM29721277X | ||
| 035 | |a (NLM)31102728 | ||
| 035 | |a (PII)S1359-6446(18)30036-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheong, Siew L |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The current status of pharmacotherapy for the treatment of Parkinson's disease |b transition from single-target to multitarget therapy |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.06.2020 | ||
| 500 | |a Date Revised 11.06.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Parkinson's disease (PD) is a neurodegenerative disorder characterized by degeneration of dopaminergic neurons. Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. Current treatment options provide symptomatic relief to the condition but are unable to reverse disease progression. The conventional single-target therapeutic approach might not always induce the desired effect owing to the multifactorial nature of PD. Hence, multitarget strategies have been proposed to simultaneously target multiple proteins involved in the development of PD. Herein, we provide an overview of the pathogenesis of PD and the current pharmacotherapies. Furthermore, rationales and examples of multitarget approaches that have been tested in preclinical trials for the treatment of PD are also discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antiparkinson Agents |2 NLM | |
| 700 | 1 | |a Federico, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Spalluto, Giampiero |e verfasserin |4 aut | |
| 700 | 1 | |a Klotz, Karl-Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Pastorin, Giorgia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug discovery today |d 1998 |g 24(2019), 9 vom: 01. Sept., Seite 1769-1783 |w (DE-627)NLM095449159 |x 1878-5832 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2019 |g number:9 |g day:01 |g month:09 |g pages:1769-1783 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drudis.2019.05.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2019 |e 9 |b 01 |c 09 |h 1769-1783 | ||